Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 71, n° 6
pages 1144-1150 (décembre 2014)
Doi : 10.1016/j.jaad.2014.09.012
accepted : 4 September 2014
Original Articles

Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis
 

Julia Shlyankevich, MD a, b, c, Allison J. Chen, BA c, Grace E. Kim, BS a, b, d, Alexandra B. Kimball, MD, MPH a, b, d,
a Clinical Unit for Research Trials and Outcomes in Skin, Massachusetts General Hospital, Boston, Massachusetts 
b Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts 
c Alpert Medical School, Brown University, Providence, Rhode Island 
d Harvard Medical School, Boston, Massachusetts 

Reprint requests: Alexandra B. Kimball, MD, MPH, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St, Suite 240, Boston, MA 02114.
Abstract
Background

Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving intertriginous skin. Previous epidemiologic studies have been limited by small sample size.

Objective

We sought to describe the prevalence and comorbidities of HS in a large patient care database.

Methods

In this retrospective case-control study, we chart-validated all patients within a hospital database who received at least 1 billing code for HS between 1980 and 2013. Verified cases were matched with controls based on age, gender, and race. Prevalences of a priori selected comorbidities were compared between HS and control groups.

Results

A total of 2292 patients at Massachusetts General Hospital received at least 1 code for HS. A total of 1776 cases had a validated diagnosis of HS, yielding a prevalence of 0.08%. In unadjusted analysis, all comorbidities were diagnosed significantly more in HS compared with control including (in rank order of likelihood): smoking, arthropathies, dyslipidemia, polycystic ovarian syndrome, psychiatric disorders, obesity, drug dependence, hypertension, diabetes, thyroid disease, alcohol dependence, and lymphoma (all P < .01).

Limitations

Control subjects were not validated for absence of HS and comorbidity validation was not performed for either group.

Conclusions

Our results highlights the high comorbidity burden of patients with HS compared with matched control subjects.

The full text of this article is available in PDF format.

Key words : acne inversa, cardiovascular disease, comorbidities, hidradenitis, hidradenitis suppurativa, lymphoma, metabolic syndrome, obesity, prevalence

Abbreviations used : CI, HS, ICD-9 , OR, PCOS, RPDR, SCC



 Dr Shlyankevich has partial fellowship funding from Janssen.
 Disclosure: Dr Kimball has served as an investigator and consultant for Abbvie. Dr Shlyankevich has partial fellowship funding from Janssen. Ms Chen and Ms Kim have no conflicts of interest to declare.



© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline